Please login to the form below
New Accounts, April, 2008 - Advertising
New pharmaceutical account wins notified to us by the winning agency for the period January, 2008 to March, 2008 inclusive
New pharmaceutical account wins notified to us by the winning agency for the period January, 2008 to March, 2008 inclusive
| CLIENT | PRODUCT | THERAPEUTIC AREA | WINNING AGENCY |
| Baxter Healthcare UK | Brevibloc | Cardiology | WBR |
| Baxter Healthcare UK | Suprane | Anaesthesiology | WBR |
| Menarini | Migard | Migraine | Saatchi & Saatchi Healthcare |
| Sanofi Pasteur MSD | Travel vaccines portfolio | Vaccine | Woolley Pau |
| Wyeth | Prostap | Urology | Oak |
Please note that inclusion in this table does not necessarily indicate exclusivity and other agencies may not be involved with some of the products listed in other ways, or in domestic, overseas or international markets. To submit an entry for New Accounts, email new_accounts@pmlive.com
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- AZ/Oxford University vaccine shows 82.4% efficacy with extended dosing schedule
- Pfizer/BioNTech to develop a booster dose for their COVID-19 vaccine
- STEM Healthcare founder Rob Wood secures a 25% stake in performance-io
- FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
- GSK launches late-stage testing of RSV vaccine candidate in older adults
- FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
- UK introduces Rare Diseases Framework to improve the lives of people with rare diseases
- Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease
- UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’
- Merck to acquire Pandion Therapeutics for $1.85bn
- bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video
PMHub
Syneos Health®
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...
Latest intelligence
- 4 ways to recruit Alzheimer’s disease patients for your clinical trial
- What key things do you need to remember to reach patients living with Alzheimer’s disease?...
- Integrating competitive intelligence into business development, licensing and M&A strategy
- The advantages of partnering with a competitive intelligence or knowledge management team...
- Reaching patients and HCPs during the pandemic
- COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
Quick links
Infographics
